Gulf International Bank UK Ltd Lowers Holdings in Insulet Co. (NASDAQ:PODD)

Gulf International Bank UK Ltd lessened its stake in Insulet Co. (NASDAQ:PODD) by 2.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,452 shares of the medical instruments supplier’s stock after selling 133 shares during the quarter. Gulf International Bank UK Ltd’s holdings in Insulet were worth $1,423,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of PODD. Mn Services Vermogensbeheer B.V. raised its position in Insulet by 2.2% in the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 27,400 shares of the medical instruments supplier’s stock worth $7,153,000 after buying an additional 600 shares during the last quarter. New York Life Investment Management LLC raised its position in Insulet by 79.6% in the 4th quarter. New York Life Investment Management LLC now owns 16,854 shares of the medical instruments supplier’s stock worth $4,400,000 after buying an additional 7,471 shares during the last quarter. Allianz Asset Management GmbH raised its position in Insulet by 27.7% in the 4th quarter. Allianz Asset Management GmbH now owns 113,921 shares of the medical instruments supplier’s stock worth $29,741,000 after buying an additional 24,734 shares during the last quarter. ING Groep NV purchased a new position in Insulet in the 4th quarter worth about $556,000. Finally, Handelsbanken Fonder AB raised its position in Insulet by 9.9% in the 4th quarter. Handelsbanken Fonder AB now owns 18,916 shares of the medical instruments supplier’s stock worth $4,938,000 after buying an additional 1,700 shares during the last quarter.

Insiders Place Their Bets

In other Insulet news, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

Insulet Trading Up 1.9 %

Shares of NASDAQ:PODD opened at $272.27 on Friday. The stock has a 50 day moving average of $274.01 and a 200 day moving average of $250.30. The company has a market cap of $19.12 billion, a PE ratio of 47.02, a price-to-earnings-growth ratio of 3.62 and a beta of 1.23. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. As a group, equities research analysts expect that Insulet Co. will post 3.92 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on PODD. BTIG Research boosted their target price on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. JPMorgan Chase & Co. boosted their target price on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research report on Thursday, December 12th. Wells Fargo & Company boosted their price target on Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Sanford C. Bernstein assumed coverage on Insulet in a research note on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target for the company. Finally, Morgan Stanley boosted their price target on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $289.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.